The Scientist3 年
It’s All in the Timing: Optimizing Chemotherapy Administration
Sejal Davla is a neuroscientist with a PhD from McGill University and a science storyteller. As a science editor for The Scientist’s Creative Services Team, she develops stories about the latest ...
Pharmaceutical Technology on MSN15 天
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
Medscape15 天
Tislelizumab Receives First-Line Nod for Unresectable/Metastatic ESCC
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or ...
Monthly Prescribing Reference15 天
Tevimbra Plus Chemotherapy Approved as First-Line Tx for Advanced Esophageal Cancer
Overall survival was statistically significantly improved in adults treated with tislelizumab/chemotherapy compared with placebo/chemotherapy. The Food and Drug ...
Cancer Therapy Advisor15 天
Tevimbra Plus Chemotherapy Approved as First-Line Tx for Advanced Esophageal Cancer
The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy as first-line treatment for unresectable or metastatic, PD-L1-positive ESCC.
The Pharma Letter15 天
New US approval for BeiGene’s Tevimbra
The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or ...